168 related articles for article (PubMed ID: 37116859)
1. DNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer.
Wei SJ; Yang IH; Mohiuddin IS; Kshirsagar GJ; Nguyen TH; Trasti S; Maurer BJ; Kang MH
Biochim Biophys Acta Gene Regul Mech; 2023 Jun; 1866(2):194939. PubMed ID: 37116859
[TBL] [Abstract][Full Text] [Related]
2. MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma.
Wei SJ; Nguyen TH; Yang IH; Mook DG; Makena MR; Verlekar D; Hindle A; Martinez GM; Yang S; Shimada H; Reynolds CP; Kang MH
Cell Death Dis; 2020 May; 11(5):368. PubMed ID: 32409685
[TBL] [Abstract][Full Text] [Related]
3. Development of cell-based high throughput luminescence assay for drug discovery in inhibiting OCT4/DNA-PKcs and OCT4-MK2 interactions.
Mohiuddin IS; Wei SJ; Yang IH; Martinez GM; Yang S; Cho EJ; Dalby KN; Kang MH
Biotechnol Bioeng; 2021 May; 118(5):1987-2000. PubMed ID: 33565603
[TBL] [Abstract][Full Text] [Related]
4. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of c-myc protein by siRNA-mediated silencing of DNA-PKcs in HeLa cells.
An J; Xu QZ; Sui JL; Bai B; Zhou PK
Int J Cancer; 2005 Nov; 117(4):531-7. PubMed ID: 15929110
[TBL] [Abstract][Full Text] [Related]
6. DNA-dependent protein kinase catalytic subunit modulates the stability of c-Myc oncoprotein.
An J; Yang DY; Xu QZ; Zhang SM; Huo YY; Shang ZF; Wang Y; Wu DC; Zhou PK
Mol Cancer; 2008 Apr; 7():32. PubMed ID: 18426604
[TBL] [Abstract][Full Text] [Related]
7. Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer.
Shatat MA; Gauthier B; Yoon S; Yuan E; Yang P; Narla G; Dowlati A; Lee RT
Cancer Med; 2023 Apr; 12(7):8378-8387. PubMed ID: 36562288
[TBL] [Abstract][Full Text] [Related]
8. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer.
Kim DW; Wu N; Kim YC; Cheng PF; Basom R; Kim D; Dunn CT; Lee AY; Kim K; Lee CS; Singh A; Gazdar AF; Harris CR; Eisenman RN; Park KS; MacPherson D
Genes Dev; 2016 Jun; 30(11):1289-99. PubMed ID: 27298335
[TBL] [Abstract][Full Text] [Related]
9. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
[TBL] [Abstract][Full Text] [Related]
10. MYCL1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected Small-Cell Lung Carcinoma.
Qin J; Xie F; Li C; Han N; Lu H
Pathol Oncol Res; 2021; 27():1609775. PubMed ID: 34257619
[No Abstract] [Full Text] [Related]
11. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
[TBL] [Abstract][Full Text] [Related]
12. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
[TBL] [Abstract][Full Text] [Related]
13. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
[TBL] [Abstract][Full Text] [Related]
14. Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer.
Patel AS; Yoo S; Kong R; Sato T; Sinha A; Karam S; Bao L; Fridrikh M; Emoto K; Nudelman G; Powell CA; Beasley MB; Zhu J; Watanabe H
Sci Adv; 2021 Jan; 7(5):. PubMed ID: 33514539
[TBL] [Abstract][Full Text] [Related]
15. Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status.
Suda K; Rozeboom L; Yu H; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
PLoS One; 2017; 12(2):e0172209. PubMed ID: 28192473
[TBL] [Abstract][Full Text] [Related]
16. Myc protein expression correlates with MYC amplification in small-cell lung carcinoma.
Hwang DH; Sun H; Rodig SJ; Hornick JL; Sholl LM
Histopathology; 2015 Jul; 67(1):81-9. PubMed ID: 25407018
[TBL] [Abstract][Full Text] [Related]
17. Family matters: How MYC family oncogenes impact small cell lung cancer.
Brägelmann J; Böhm S; Guthrie MR; Mollaoglu G; Oliver TG; Sos ML
Cell Cycle; 2017 Aug; 16(16):1489-1498. PubMed ID: 28737478
[TBL] [Abstract][Full Text] [Related]
18. Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells.
Jull BA; Plummer HK; Schuller HM
J Cancer Res Clin Oncol; 2001 Dec; 127(12):707-17. PubMed ID: 11768610
[TBL] [Abstract][Full Text] [Related]
19. Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer.
Huang F; Huffman KE; Wang Z; Wang X; Li K; Cai F; Yang C; Cai L; Shih TS; Zacharias LG; Chung A; Yang Q; Chalishazar MD; Ireland AS; Stewart CA; Cargill K; Girard L; Liu Y; Ni M; Xu J; Wu X; Zhu H; Drapkin B; Byers LA; Oliver TG; Gazdar AF; Minna JD; DeBerardinis RJ
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33079728
[TBL] [Abstract][Full Text] [Related]
20. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
